Literature DB >> 25614310

Parkinsonism in phenylketonuria: a consequence of dopamine depletion?

Marieke Velema1, Erik Boot, Marc Engelen, Carla Hollak.   

Abstract

Phenylketonuria (PKU) is caused by a deficiency or inactivity of the enzyme phenylalanine hydroxylase that converts phenylalanine (Phe) to tyrosine (Tyr). It has been proposed that a reduction of brain Tyr levels, as well as reduced activity of the key regulatory enzyme of dopamine (DA) synthesis tyrosine hydroxylase, leads to a depletion in DA activity in patients with PKU. We report a case of a 56-year-old woman with an intellectual disability due to late diagnosis of PKU and parkinsonism, with a modest clinical response to levodopa therapy.We hypothesize that the signs of parkinsonism might be caused by the depletion of DA activity in the brain. Clinicians should be alert on parkinsonian symptoms in patients with PKU, particularly in those treated with agents that negatively influence DA transmission.

Entities:  

Year:  2015        PMID: 25614310      PMCID: PMC4375126          DOI: 10.1007/8904_2014_386

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  21 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment.

Authors:  J Pietz; R Kreis; H Schmidt; U K Meyding-Lamadé; A Rupp; C Boesch
Journal:  Radiology       Date:  1996-11       Impact factor: 11.105

3.  A neurological evaluation of adult phenylketonuria in Northern Ireland.

Authors:  G V McDonnell; T F Esmonde; D R Hadden; J I Morrow
Journal:  Eur Neurol       Date:  1998       Impact factor: 1.710

Review 4.  Adult care in phenylketonuria and hyperphenylalaninaemia: the relevance of neurological abnormalities.

Authors:  D P Brenton; J Pietz
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

5.  Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™).

Authors:  Jeffrey L Cummings; Michael J Fine; Igor D Grachev; C Rick Jarecke; Meridith K Johnson; Phillip H Kuo; Kenneth L Schaecher; Joyce A Oberdorf; Michael Rezak; David E Riley; Daniel Truong
Journal:  Am J Manag Care       Date:  2014-03       Impact factor: 2.229

6.  D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study.

Authors:  T Brücke; C Wöber; I Podreka; C Wöber-Bingöl; S Asenbaum; S Aull; S Wenger; D Ilieva; C Harasko-van der Meer; P Wessely
Journal:  J Cereb Blood Flow Metab       Date:  1995-05       Impact factor: 6.200

7.  Neurological outcome in adult patients with early-treated phenylketonuria.

Authors:  J Pietz; R Dunckelmann; A Rupp; D Rating; H M Meinck; H Schmidt; H J Bremer
Journal:  Eur J Pediatr       Date:  1998-10       Impact factor: 3.183

8.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.

Authors:  Claudia Ramaker; Johan Marinus; Anne Margarethe Stiggelbout; Bob Johannes Van Hilten
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

9.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

10.  Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis.

Authors:  Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Harold W de Valk; Anne M J Paans; Pieter J J Sauer; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2013-09-04       Impact factor: 4.123

View more
  7 in total

Review 1.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study.

Authors:  Eszter Juhász; Erika Kiss; Erika Simonova; Attila Patócs; Peter Reismann
Journal:  Eur J Med Res       Date:  2016-05-11       Impact factor: 2.175

Review 3.  Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders.

Authors:  Karolina M Stepien; Robert Heaton; Scott Rankin; Alex Murphy; James Bentley; Darren Sexton; Iain P Hargreaves
Journal:  J Clin Med       Date:  2017-07-19       Impact factor: 4.241

4.  The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.

Authors:  Miroslaw Bik-Multanowski; Kinga Bik-Multanowska; Iwona Betka; Anna Madetko-Talowska
Journal:  Mol Genet Metab Rep       Date:  2021-03-31

Review 5.  Engineering Organoids for in vitro Modeling of Phenylketonuria.

Authors:  Alice C Borges; Kerensa Broersen; Paula Leandro; Tiago G Fernandes
Journal:  Front Mol Neurosci       Date:  2022-01-10       Impact factor: 5.639

6.  Disruption of phenylalanine hydroxylase reduces adult lifespan and fecundity, and impairs embryonic development in parthenogenetic pea aphids.

Authors:  Pierre Simonet; Karen Gaget; Nicolas Parisot; Gabrielle Duport; Marjolaine Rey; Gérard Febvay; Hubert Charles; Patrick Callaerts; Stefano Colella; Federica Calevro
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

Review 7.  Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features.

Authors:  Nattakarn Limphaibool; Piotr Iwanowski; Marte Johanne Veilemand Holstad; Katarzyna Perkowska
Journal:  Front Neurol       Date:  2018-10-12       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.